Compounds > prednisone
Page last updated: 2024-11-07

prednisone and Pancreatic Diseases

prednisone has been researched along with Pancreatic Diseases in 16 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Pancreatic Diseases: Pathological processes of the PANCREAS.

Research Excerpts

ExcerptRelevanceReference
"Pancreatitis is the most common major complication of diagnostic and therapeutic ERCP."2.71Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. ( Aliperti, G; Barnett, J; Blaut, U; Dua, KS; Earle, D; Fogel, EL; Frakes, JT; Freeman, M; Geenen, J; Goff, J; Jones, W; Lehman, GA; Parker, H; Ryan, M; Sherman, S; Silverman, WB; Temkit, M; Uzer, M; Watkins, JL; Yakshe, P, 2003)
"Pyoderma gangrenosum is a dermatological disease of unknown origin."2.39Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. ( Arpurt, JP; Bartel, HR; Bodock, I; Caroli-Bosc, FX; Delmont, JP; Dumas, R; Harris, AG; Hastier, P; Maes, B; Taillan, B, 1996)
"A presumptive diagnosis of chronic periaortitis was made, and a dramatic response to corticosteroid therapy was subsequently observed."1.29Pseudotumor of the pancreas associated with retroperitoneal fibrosis: a dramatic response to corticosteroid therapy. ( Boyer, JL; Burrell, MI; Chutaputti, A, 1995)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-199010 (62.50)18.7374
1990's4 (25.00)18.2507
2000's1 (6.25)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Deng, X1
Fang, R1
Zhang, J1
Li, R1
Sherman, S1
Blaut, U1
Watkins, JL1
Barnett, J1
Freeman, M1
Geenen, J1
Ryan, M1
Parker, H1
Frakes, JT1
Fogel, EL1
Silverman, WB1
Dua, KS1
Aliperti, G1
Yakshe, P1
Uzer, M1
Jones, W1
Goff, J1
Earle, D1
Temkit, M1
Lehman, GA1
GAILLARD, L1
DELPHIN, D1
GREMILLET, J1
LINDNER, H1
Chutaputti, A1
Burrell, MI1
Boyer, JL1
Noguchi, H1
Hirai, K1
Seo, A1
Yoshitake, M1
Sakai, T1
Abe, H1
Hidaka, R1
Aritaka, T1
Tanikawa, K1
Hastier, P1
Caroli-Bosc, FX1
Bartel, HR1
Harris, AG1
Maes, B1
Arpurt, JP1
Taillan, B1
Bodock, I1
Dumas, R1
Delmont, JP1
Williams, ME1
Longmaid, HE1
Trey, G1
Federman, M1
Crosson, AW1
Lupi, L1
De Bellis, U1
Antonelli, P1
Jemma, R1
Gall, DG1
Hamilton, JR1
Coodley, EL1
Fucík, J1
Dorazilová, V1
Bell, MJ1
Martin, LW1
Gonzales, LL1
McEnery, PT1
West, CD1
Silverstein, MN1
Bayrd, ED1
Karkucińska, E1
Laroche, C1
Grégoire, J1
Caquet, R1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) - Induced Pancreatitis Using Aggressive Lactated Ringer's Infusion and/or Rectal Indomethacin[NCT02641561]Phase 3192 participants (Actual)Interventional2014-10-31Completed
Feasibility Study of a Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis[NCT01758549]62 participants (Actual)Interventional2012-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Length of Stay (LOS) of Participants After ERCP if Medical Care is Sought as Assessed in Days

(NCT02641561)
Timeframe: 30 days after ERCP

Interventiondays (Mean)
A (NS+Placebo)2.3
B (NS+IND)2.2
C (LR+Placebo)1.9
D (LR+IND)4.3

The Number of Participants Who Undergo Surgery After ERCP, as Assessed by Surgical Operative Report

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants Who Were Readmitted After ERCP as Assessed by Medical Record and Patients Self-reporting

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)6
B (NS+IND)2
C (LR+Placebo)2
D (LR+IND)1

The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Either Elevated Amylase or Lipase 3 x Upper Limit of Normal

amylase or lipase (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Imaging Suggestive of Acute Pancreatitis

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)1
C (LR+Placebo)0
D (LR+IND)1

The Number of Participants With Acute Respiratory Distress Syndrome (ARDS) After ERCP as Assessed by ARDSnet Criterion (Below)

bilateral opacities on chest imaging not explained by other lung pathology, respiratory failure not explained by heart failure or volume, and overload and a pulmonary arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio under 300, PaO2/FiO2 ratio is the partial pressure arterial oxygen and fraction of inspired oxygen (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)1
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Mortality After ERCP as Assessed by Medical Record Reporting

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)1
B (NS+IND)2
C (LR+Placebo)2
D (LR+IND)1

The Number of Participants With Multiple Organ Failure (MOF) After ERCP as Assessed by Elevated Creatinine Blood Test

creatinine > 1.5 milligrams/deciliter (mg/dL) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)1
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Multiple Organ Failure (MOF) After ERCP as Assessed by Elevated International Normalized Ratio (INR)

INR > 1.5 (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Pancreatic Abscess After ERCP as Assessed by Abdominal Imaging Suggestive of Pancreatic Abscess

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Pancreatic Pseudocyst After ERCP as Assessed by Abdominal Imaging Suggestive of Pseudocyst

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)1

The Number of Participants With Perforation After ERCP as Assessed by Abdominal Imaging Suggestive of Perforation

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Post-procedural Medical Care (ED Visit, Urgent Care, Hospitalization) as Assessed by Medical Record and Patients Self-reporting

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)6
B (NS+IND)2
C (LR+Placebo)2
D (LR+IND)1

The Number of Participants With Sepsis After ERCP as Assessed by Infectious Source Defined by Positive Microbiology Culture

positive blood culture (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

> 10% immature neutrophils (band forms). (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

Heart rate > 90 beats per minutes (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

PaCO2 < 4.3 kilopascal (kPa) (32 mmHg) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

Respiratory rate > 20 breaths per minute (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

Temperature < 36°C(96.8°F) or > 38°C(100.4°F) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

white blood cell (WBC) count < 4000 cells/mm³ (4 x 109 cells/L) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

Reviews

4 reviews available for prednisone and Pancreatic Diseases

ArticleYear
Multivisceral IgG4-related disease presenting as recurrent massive gastrointestinal bleeding: a case report and literature review.
    BMC gastroenterology, 2018, Sep-04, Volume: 18, Issue:1

    Topics: Anti-Inflammatory Agents; Autoimmune Diseases; Diagnostic Errors; Digestive System Diseases; Duodena

2018
Sarcoidosis accompanied by pancreatic impairment.
    Internal medicine (Tokyo, Japan), 1993, Volume: 32, Issue:1

    Topics: Humans; Male; Middle Aged; Pancreas; Pancreatic Diseases; Prednisone; Sarcoidosis

1993
Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis.
    Digestive diseases and sciences, 1996, Volume: 41, Issue:3

    Topics: Arthritis, Rheumatoid; Female; Humans; Liver Diseases; Middle Aged; Pancreatic Diseases; Prednisone;

1996
Chronic diarrhea in childhood: a new look at an old problem.
    Pediatric clinics of North America, 1974, Volume: 21, Issue:4

    Topics: Celiac Disease; Chlorides; Chronic Disease; Cystic Fibrosis; Diarrhea; Diet Therapy; Food Hypersensi

1974

Trials

1 trial available for prednisone and Pancreatic Diseases

ArticleYear
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
    Gastrointestinal endoscopy, 2003, Volume: 58, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Chi-Square Distribution; Cholangiopancreatograp

2003
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
    Gastrointestinal endoscopy, 2003, Volume: 58, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Chi-Square Distribution; Cholangiopancreatograp

2003
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
    Gastrointestinal endoscopy, 2003, Volume: 58, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Chi-Square Distribution; Cholangiopancreatograp

2003
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
    Gastrointestinal endoscopy, 2003, Volume: 58, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Chi-Square Distribution; Cholangiopancreatograp

2003

Other Studies

11 other studies available for prednisone and Pancreatic Diseases

ArticleYear
[Hypoglycemic coma after the stopping of delta-cortisone therapy].
    Pediatrie, 1958, Volume: 13, Issue:3

    Topics: Child; Coma; Humans; Hypoglycemia; Hypoglycemic Agents; Infant; Pancreatic Diseases; Prednisone

1958
[ACUTE PANCREATITIS (PANCREATIC NECROSIS) CAUSED BY GLUCOCORTICOID THERAPY].
    Deutsche medizinische Wochenschrift (1946), 1964, Apr-24, Volume: 89

    Topics: Geriatrics; Jaundice; Liver Cirrhosis; Pancreatic Diseases; Pancreatitis; Prednisone; Toxicology

1964
Pseudotumor of the pancreas associated with retroperitoneal fibrosis: a dramatic response to corticosteroid therapy.
    The American journal of gastroenterology, 1995, Volume: 90, Issue:7

    Topics: Aged; Diagnosis, Differential; Humans; Male; Pancreatic Diseases; Pancreatic Neoplasms; Prednisone;

1995
Renal failure resulting from infiltration by inflammatory myofibroblastic tumor responsive to corticosteroid therapy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1998, Volume: 31, Issue:6

    Topics: Acute Kidney Injury; Aged; Biopsy; Glucocorticoids; Granuloma, Plasma Cell; Humans; Kidney; Kidney D

1998
[Severe hemochromatosis after transfusion in a girl with Blackfan-Diamond anemia].
    Minerva pediatrica, 1977, Apr-07, Volume: 29, Issue:12

    Topics: Anemia, Aplastic; Child; Child, Preschool; Erythrocytes, Abnormal; Female; Hemochromatosis; Humans;

1977
Diagnostic modalities in jaundice.
    The American journal of gastroenterology, 1970, Volume: 54, Issue:2

    Topics: Biopsy; Catheterization; Cholangiography; Cholestasis; Diagnosis, Differential; Hepatic Artery; Hepa

1970
[Polyarthritis nodosa with marked hepatic and pancreatic involvement and associated with the diabetic syndrome].
    Vnitrni lekarstvi, 1970, Volume: 16, Issue:8

    Topics: Autopsy; Diabetes Complications; Fatty Liver; Humans; Male; Middle Aged; Necrosis; Pancreatic Diseas

1970
Alternate-day single-dose prednisone therapy: a method of reducing steroid toxicity.
    Journal of pediatric surgery, 1972, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Azathioprine; Bacterial Infections; Bone Diseases; Cataract; Child; Child, Presch

1972
Nonmeningeal extramedullary relapse in leukemia.
    Archives of internal medicine, 1969, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Bone Diseases; Bone Marrow; Bone Marrow Cells; Child; Female; Gallbladder Disease

1969
[Acute necrosis of the pancreas in a child treated with prednisone].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1970, Mar-15, Volume: 23, Issue:6

    Topics: Adolescent; Female; Humans; Necrosis; Pancreas; Pancreatic Diseases; Prednisone; Rheumatic Fever

1970
[Can organic hypoglycemia in adults be medically treated?].
    Semaine therapeutique, 1968, Volume: 44, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Age Factors; Diazoxide; Diet Therapy; Drug Synergism; Hormones; Huma

1968